Navigation Links
Laszlo Radvanyi, Ph.D. Joins Genesis Biopharma Scientific and Medical Advisory Board
Date:7/5/2011

LOS ANGELES, July 5, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer therapies, today announced Laszlo Radvanyi, Ph.D., an Associate Professor in the Department of Melanoma Medical Oncology Research at the University of Texas MD Anderson Cancer Center in Houston, has joined its Scientific and Medical Advisory Board.  MD Anderson is one of the world's premier cancer centers, conducting advanced research and education programs and providing patient care.

"Dr. Radvanyi's research using tumor-infiltrating lymphocytes (TILs) for the treatment of Stage IV metastatic melanoma, including ongoing Phase I and Phase II clinical trials, complements the development of our product candidate Contego™ for the treatment of Stage IV metastatic melanoma," stated Anthony J. Cataldo, Chairman and Chief Executive Officer of Genesis Biopharma.  "Dr. Radvanyi's knowledge and expertise in growing TILs ex vivo will be helpful as we scale-up the manufacture of Contego in anticipation of the commencement of clinical trials for Contego."

Dr. Radvanyi received his Ph.D. in clinical biochemistry from the University of Toronto.  His main research area is tumor immunology studying immune regulation in cancer and identifying new antigens as targets for anti-cancer T-cell therapy.  After completing postdoctoral work in Toronto and at Harvard University in Boston at the Joslin Diabetes Center, Dr. Radvanyi joined the Immunology Group at Sanofi-Pasteur in Toronto in 2000 as a Senior Scientist where he helped lead an antigen discovery program that led to the discovery of a group of over-expressed breast cancer-specific genes that are candidates for antigen-specific vaccines against breast cancer. In 2005, Dr. Radvanyi joined the faculty of the University of Texas, MD Anderson Cancer Center as an Associate Professor.  He has a dual appointment in the Departments of Breast Medical Oncolog
'/>"/>

SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
2. WuXi AppTec Appoints Garry Takle, Ph.D. as VP of Operations and Joseph Hughes, Ph.D. as VP of Testing Services for Philadelphia Facility
3. Takeda San Francisco, Inc. Appoints Gregory Landes, Ph.D. Vice President of Antibody Research
4. Exosome Diagnostics Appoints Johan Skog, Ph.D., as Director of Genetics Research
5. David Hsia, Ph.D. Joins Kinex Pharmaceuticals Board of Directors
6. Cato T. Laurencin, M.D., Ph.D. to Join Osteotech Board of Directors
7. Two Luminaries Join Cequent Scientific Advisory Board: Judy Lieberman, M.D. Ph.D., and Patrice Courvalin, M.D.
8. SENOMYX CO-FOUNDER AND SCIENTIFIC ADVISORY BOARD MEMBER ROGER TSIEN, PH.D., AWARDED NOBEL PRIZE IN CHEMISTRY
9. Brain and Hearing Pioneer, Michael Merzenich, Ph.D. to Speak at Case Western Reserve University
10. James L. Wittliff, Ph.D., FACB, to Present Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System at the Association for Molecular Pathology Conference, October 30
11. ALine, Inc. Expands Management, Adding Roger Anderson, Ph.D., as VP of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... MA (PRWEB) May 22, 2013 Cambridge ... present at last week’s “Data Demonstration Day” on Capitol Hill, ... Semantics joined EMC, Google, Microsoft and others to showcase how ... proposed Digital Accountability and Transparency Act (DATA Act). , Originally ... Issa (R-CA) and Sen. Mark Warner ...
(Date:5/22/2013)... The Conference Forum announced ... Advance Clinical Trials conference taking place on September 19-20 ... , Disruptive thinkers from Novartis, Pfizer, Eli Lilly, ... approaches to reduce expensive infrastructure, engage patients and generate ... be big, or novel, or it must change the ...
(Date:5/22/2013)... YORK , May 22, 2013   ... the development of disease modifying therapeutics for Alzheimer,s ... the completion of its Series B financing, which ... and warrants that would represent approximately $2.8M in ... and new investors supported the raise. ...
(Date:5/22/2013)... May 22, 2013  Empire Genomics announced today ... patent pending novel genomic biomarker from Cornell University ... that could help in diagnosing and determining treatment ... Neuroendocrine prostate cancer (NEPC) is a ... arise de novo, but more commonly arises after ...
Breaking Biology Technology:Cambridge Semantics Underscores Need for Smart Data during “Data Demonstration Day” on Capitol Hill 2Disruptive Innovation Hits Clinical Trials, Dedicated Event Launches 2Oligomerix, Inc. Completes Series B Financing 2Oligomerix, Inc. Completes Series B Financing 3Empire Genomics Licenses Novel DNA Biomarker for Use in Diagnosing and Creating a Companion Diagnostic Test for Neuroendocrine Prostate Cancer 2
... Remedy Informatics, the leading provider of registries for Life ... Providence Health & Services, has selected Remedy,s Mosaic(TM) ... Telestroke Network to improve patient outcomes . ... excited to work with Providence, and to support their ...
... (NASDAQ: CPHD ) today announced that, together ... Jersey (UMDNJ), it has received a grant from the ... amplification methods for highly-sensitive detection of bloodstream bacteria using ... The $1.3 million grant is for the first year ...
... BOSTON, Massachusetts, March 20, 2012 Heptares ... an operating company of Shire PLC (LSE: SHP, NASDAQ: ... has exercised its exclusive option to license a novel ... is currently in preclinical development. Adenosine A 2A ...
Cached Biology Technology:Providence Health & Services Inks Deal with Remedy Informatics for Orthopedic and Stroke Registries 2Providence Health & Services Inks Deal with Remedy Informatics for Orthopedic and Stroke Registries 3Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria 2Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria 3Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria 4Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders 2Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders 3
(Date:5/21/2013)... , May 21, 2013 Royal Philips Electronics ... the world,s first portable ultrasound with Philips, industry leading ... capability. The CX50 xMATRIX with available Live 3D TEE ... at the EuroPCR, official meeting for the ... Since its launch in 2012, Philips CX50 ...
(Date:5/20/2013)... also commonly resistant to antimicrobial substances made by ... mBio , the online open-access journal of ... and host antimicrobials LL-37 and lysozyme, which help ... that patients with life-threatening multi-drug resistant infections are ... is a last-line drug for treating several kinds ...
(Date:5/20/2013)... the effect of physical education (PE) on child weight, ... increasing the amount of time that elementary schoolchildren spent ... The study represents some of the first evidence of ... is forthcoming in the Journal of Health Economics ... can be viewed at: http://www.sciencedirect.com/science/article/pii/S0167629613000556 , The ...
Breaking Biology News(10 mins):Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3Gym class reduces probability of obesity, study finds for first time 2
... planning of the preparatory activities for a new tentative ... satellite. On 7 September, preparatory activities for the ... Russia were stopped by Eurockot due to an anomaly ... and navigation subsystem of the launcher,s Upper Stage Breeze ...
... a highly selective behavior towards odor stimuli. A ... olfactory stimulus is often not sufficient for immediate ... Interestingly, the behavior differed between investigated D. ... mangos) were preferred by most flies, whereas artificial ...
... 1 OCTOBER 2008 Not only are more than ... Brown Convention Center, beginning this weekend, to participate in ... but they are bringing focus to issues of local ... theme of "Celebrating the International Year of Planet Earth," ...
Cached Biology News:What is wild? Odor attraction among different wildtype Drosophila 2What is wild? Odor attraction among different wildtype Drosophila 3Earth scientists keep an eye on Texas 2Earth scientists keep an eye on Texas 3Earth scientists keep an eye on Texas 4Earth scientists keep an eye on Texas 5
...
Mouse monoclonal antibody to PDK2 - pyruvate dehydrogenase kinase, isoenzyme 2...
Mouse polyclonal antibody raised against a partial recombinant WRB. NCBI Entrez Gene ID = 7485...
Mouse monoclonal antibody raised against a partial recombinant PRG4. NCBI Entrez Gene ID = PRG4...
Biology Products: